Business Context and Reporting Period
This Form 8-K Current Report was filed by PharmAthene, Inc. (not Altimmune, Inc.) on March 25, 2013. The filing discloses the entry into a material definitive agreement to facilitate an equity offering.
Key Financial Metrics and Capital Structure
- Offering Capacity: The Company may offer and sell shares of common stock with an aggregate offering price of up to $15.0 million.
- Outstanding Shares: As of February 28, 2013, there were 48,365,984 shares of Common Stock outstanding.
- Authorized Shares: The Company is authorized to issue 100,000,000 shares of Common Stock.
- Transaction Costs: The Company will pay a 3.0% commission on gross proceeds and reimburse legal fees up to $50,000.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes and Agreements
On March 25, 2013, PharmAthene, Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. as the sales agent. This agreement allows for "at-the-market" offerings on the NYSE MKT or other trading markets. The Company is not obligated to sell any shares under this agreement and may instruct the agent not to sell if prices fall below designated levels.
Outlook, Risks, and Management Commentary
- Use of Proceeds: Net proceeds, if any, will be used for general corporate purposes, including working capital, research and development, general and administrative expenses, and capital expenditures.
- Termination: The agreement terminates upon the sale of $15.0 million in shares or upon 10 days' notice by either party. Cantor may also terminate in the event of a material adverse change.
- Risk Factors: The filing notes that the agreement is not intended to provide factual information about the current state of affairs and directs investors to other SEC filings for such data.
Investor Verification Checklist
- Verify the current share price to assess potential dilution from the $15.0 million offering.
- Review the Company's most recent 10-K or 10-Q for actual cash flow and liquidity positions, as this 8-K does not contain financial statements.
- Confirm the status of the Form S-3 Registration Statement (File No. 333-175394) referenced in the filing.
- Monitor future filings to determine if and when shares are actually sold under this agreement.